Scholarlink

<p>This retrospective study evaluated the comparative efficacy and safety of short-term spinal cord stimulation (st-SCS) and pulsed radiofrequency (PRF) therapy in 275 patients with thoracic herpes zoster-associated neuralgia (ZAN) treated between January 2022 and August 2024. Patients were stratified by disease duration into acute (≤ 30 days), subacute (30–90 days), and postherpetic (≥ 90 days) phases. The st-SCS group (<i>n</i> = 127) demonstrated superior pain relief at 3, 6, and 12 months post-treatment compared to the PRF group (<i>n</i> = 148), particularly in subacute and postherpetic phases (<i>P</i> &lt; 0.05). While no significant intergroup difference was observed in the acute phase (<i>P</i> &gt; 0.05), st-SCS showed significantly better outcomes in subsequent phases. The st-SCS group exhibited higher preoperative PQSI scores during the acute phase (<i>P</i> &lt; 0.05) and improved BPI scores at 1-month follow-up (<i>P</i> &lt; 0.05). Both interventions significantly reduced HADS-A and HADS-D scores at all time points (<i>P</i> &lt; 0.05), with st-SCS demonstrating superior long-term improvement in depression scores (<i>P</i> &lt; 0.05). These findings suggest that st-SCS provides more effective and sustained pain relief, along with greater improvements in sleep quality, emotional well-being, and quality of life compared to PRF in the management of thoracic herpes zoster-associated neuralgia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative efficacy and safety of pulsed radiofrequency versus spinal cord stimulation in thoracic herpes zoster pain: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Fuyuan Feng,
  • Zhimin Long,
  • Ling Qiu,
  • Yue Zhang,
  • Changhe Ren,
  • Cehua Ou,
  • Jia Fu

摘要

This retrospective study evaluated the comparative efficacy and safety of short-term spinal cord stimulation (st-SCS) and pulsed radiofrequency (PRF) therapy in 275 patients with thoracic herpes zoster-associated neuralgia (ZAN) treated between January 2022 and August 2024. Patients were stratified by disease duration into acute (≤ 30 days), subacute (30–90 days), and postherpetic (≥ 90 days) phases. The st-SCS group (n = 127) demonstrated superior pain relief at 3, 6, and 12 months post-treatment compared to the PRF group (n = 148), particularly in subacute and postherpetic phases (P < 0.05). While no significant intergroup difference was observed in the acute phase (P > 0.05), st-SCS showed significantly better outcomes in subsequent phases. The st-SCS group exhibited higher preoperative PQSI scores during the acute phase (P < 0.05) and improved BPI scores at 1-month follow-up (P < 0.05). Both interventions significantly reduced HADS-A and HADS-D scores at all time points (P < 0.05), with st-SCS demonstrating superior long-term improvement in depression scores (P < 0.05). These findings suggest that st-SCS provides more effective and sustained pain relief, along with greater improvements in sleep quality, emotional well-being, and quality of life compared to PRF in the management of thoracic herpes zoster-associated neuralgia.